Alemtuzumab Shows Promise in Reducing GVHD for Asian HCT Patients
Allogeneic hematopoietic cell transplantation (HCT) is a widely used curative treatment for individuals with inborn errors of immunity (IEI).
This procedure involves the infusion of stem cells from a compatible donor to replace the defective cells in the patient’s body.
Know in Detail: https://thelifesciencesmag...
#Alemtuzumab #campath #anticd52 #multiplesclerosis #MS #Immunotherapy #DrugTherapy #Biologics #Pharma
Allogeneic hematopoietic cell transplantation (HCT) is a widely used curative treatment for individuals with inborn errors of immunity (IEI).
This procedure involves the infusion of stem cells from a compatible donor to replace the defective cells in the patient’s body.
Know in Detail: https://thelifesciencesmag...
#Alemtuzumab #campath #anticd52 #multiplesclerosis #MS #Immunotherapy #DrugTherapy #Biologics #Pharma
Alemtuzumab Shows Promise In Reducing GVHD For Asian HCT Patients | The Lifesciences Magazine
Alemtuzumab proves effective in reducing GVHD and ensuring high survival rates in Asian patients undergoing HCT for inborn errors of immunity, despite higher viral infection risks.
https://thelifesciencesmagazine.com/alemtuzumab-reducing-gvhd/
09:28 AM - Jul 31, 2024 (UTC)
